NASDAQ:DFFN - Diffusion Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.73 +0.03 (+1.11 %) (As of 02/21/2019 04:00 PM ET)Previous Close$2.70Today's Range$2.65 - $2.7352-Week Range$1.83 - $11.10Volume33,991 shsAverage Volume91,751 shsMarket Capitalization$9.22 millionP/E Ratio-0.16Dividend YieldN/ABeta-0.12 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia. Receive DFFN News and Ratings via Email Sign-up to receive the latest news and ratings for DFFN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DFFN Previous Symbol CUSIPN/A CIK1053691 Webwww.diffusionpharma.com Phone434-220-0718Debt Debt-to-Equity RatioN/A Current Ratio12.30 Quick Ratio12.30Price-To-Earnings Trailing P/E Ratio-0.16 Forward P/E Ratio-0.43 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$2.73 per share Price / Cash Flow1.00 Book Value$6.30 per share Price / Book0.43Profitability EPS (Most Recent Fiscal Year)($17.09) Net Income$-1,360,000.00 Net MarginsN/A Return on Equity-27.49% Return on Assets-24.11%Miscellaneous Employees11 Outstanding Shares3,378,000Market Cap$9.22 million Next Earnings Date4/2/2019 (Estimated) OptionableNot Optionable Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions What is Diffusion Pharmaceuticals' stock symbol? Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN." When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work? Shares of Diffusion Pharmaceuticals reverse split before market open on Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split. How were Diffusion Pharmaceuticals' earnings last quarter? Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) announced its quarterly earnings results on Wednesday, November, 14th. The company reported ($1.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $1.05. View Diffusion Pharmaceuticals' Earnings History. When is Diffusion Pharmaceuticals' next earnings date? Diffusion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for Diffusion Pharmaceuticals. What price target have analysts set for DFFN? 1 Wall Street analysts have issued 1-year price targets for Diffusion Pharmaceuticals' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate Diffusion Pharmaceuticals' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 449.5% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals. What is the consensus analysts' recommendation for Diffusion Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals. Has Diffusion Pharmaceuticals been receiving favorable news coverage? Headlines about DFFN stock have trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Diffusion Pharmaceuticals earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future. Who are some of Diffusion Pharmaceuticals' key competitors? Some companies that are related to Diffusion Pharmaceuticals include Moleculin Biotech (MBRX), Sophiris Bio (SPHS), Oncolytics Biotech (ONCY), Catabasis Pharmaceuticals (CATB), Neurotrope (NTRP), Heat Biologics (HTBX), ProPhase Labs (PRPH), AzurRx BioPharma (AZRX), Addex Therapeutics (ADDXF), Agile Therapeutics (AGRX), Leap Therapeutics (LPTX), MOTIF BIO PLC/S (MTFB), Oncomed Pharmaceuticals (OMED), Novan (NOVN) and Akari Therapeutics (AKTX). What other stocks do shareholders of Diffusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Crispr Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Atara Biotherapeutics (ATRA), Verastem (VSTM), SLS International (SLS), Madrigal Pharmaceuticals (MDGL), Global Blood Therapeutics (GBT), Exelixis (EXEL), Weyerhaeuser (WY) and TRACON Pharmaceuticals (TCON). Who are Diffusion Pharmaceuticals' key executives? Diffusion Pharmaceuticals' management team includes the folowing people: Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 70)Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 80)Mr. William Karl Hornung, Chief Financial Officer (Age 50)Mr. Thomas E. Byrne, Gen. Counsel (Age 62)Ms. Kelly Hoy, Director of Project Management Who are Diffusion Pharmaceuticals' major shareholders? Diffusion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Two Sigma Investments LP (0.95%) and Virtu Financial LLC (0.54%). Which institutional investors are selling Diffusion Pharmaceuticals stock? DFFN stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Which institutional investors are buying Diffusion Pharmaceuticals stock? DFFN stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP. How do I buy shares of Diffusion Pharmaceuticals? Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Diffusion Pharmaceuticals' stock price today? One share of DFFN stock can currently be purchased for approximately $2.73. How big of a company is Diffusion Pharmaceuticals? Diffusion Pharmaceuticals has a market capitalization of $9.22 million. The company earns $-1,360,000.00 in net income (profit) each year or ($17.09) on an earnings per share basis. Diffusion Pharmaceuticals employs 11 workers across the globe. What is Diffusion Pharmaceuticals' official website? The official website for Diffusion Pharmaceuticals is http://www.diffusionpharma.com. How can I contact Diffusion Pharmaceuticals? Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected] MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 127 (Vote Outperform)Underperform Votes: 124 (Vote Underperform)Total Votes: 251MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What is Considered a Good Return on Equity (ROE)?